HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia

Trial Profile

HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Cytarabine (Primary) ; Idarubicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2016 Planned primary completion date changed from 1 Aug 2013 to 1 Aug 2017.
    • 12 Jul 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017.
    • 19 Jan 2012 Planned number of patients changed from 100 to 50 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top